Loading...
High-dose melphalan and autologous stem-cell transplant (SCT) consolidation following induction treatment is a standard of care for newly diagnosed, SCT-eligible, multiple myeloma patients. To assess the benefit of combining the anti-CD38 monoclonal antibody daratumumab with induction therapy for these patients, European investigators conducted an industry-sponsored, multicenter, randomized, open-label, phase III trial (CASSIOPEIA) of bortezomib, thalidomide, and once-weekly dexamethasone (VTd) with or without daratumumab prior to stem-cell collection and SCT consolidation. A total of 1085 patients were equally randomized. Patients in both arms who achieved partial remission or better 100 days post-SCT underwent a second randomization to ma…